- New
PE-22-28 is a specialised research peptide developed for experimental investigation of TREK-1 (K2P2.1) potassium channel inhibition and the structure-activity relationships of spadin-derived peptides.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
Order before 15:00 for same day dispatch
Royal Mail Tracked 24
Moneyback guarantee
PE-22-28 is a synthetic seven-residue peptide corresponding to residues 22-28 of the propeptide (PE) released during the maturation of sortilin, a neuronal sorting receptor. It is a shortened form of the 17-residue peptide spadin (PE 12-28) and retains its C-terminal seven residues.
In electrophysiological and cellular research systems, PE-22-28 has been investigated as an inhibitor of the TREK-1 (K2P2.1) two-pore-domain potassium channel, with reported selectivity over the related K2P channels TREK-2, TRAAK, TRESK and TASK-1. Experimental observations depend on model system, channel expression, concentration and exposure duration, and are used to explore channel mechanisms rather than defined physiological outcomes.
Purity: ≥ 99%
Appearance: White to off-white lyophilised powder
Peptide Type: Synthetic sortilin propeptide fragment (PE 22-28)
Molecular Weight: ~773.89 g/mol
Solubility: Water, buffered aqueous solutions
Storage: –20 °C, desiccated, protected from light
Pack Size: 10 mg
Keywords: PE-22-28, PE 22-28, Spadin-Derived Peptide, Sortilin Propeptide Fragment, TREK-1, K2P Channel, Synthetic Peptide
Your review appreciation cannot be sent
Report comment
Report sent
Your report cannot be sent
Write your review
Review sent
Your review cannot be sent
Reference: NAD500
Reference: CRYSTA20
Reference: DSIP5
Reference: FOXO4
PE-22-28 is a specialised research peptide developed for experimental investigation of TREK-1 (K2P2.1) potassium channel inhibition and the structure-activity relationships of spadin-derived peptides.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
check_circle
check_circle